What is the success rate for hep C with Epclusa?

success rate of epclusa

As a doctor, I can tell you that direct-acting antivirals (DAAs) have revolutionized the treatment of hepatitis C and have led to high cure rates in most patients.

Epclusa (sofosbuvir/velpatasvir) is a widely used DAA that has been shown to cure over 90% of patients with all genotypes of HCV in as little as 12 weeks. Other DAAs, such as Mavyret (glecaprevir/pibrentasvir) and Harvoni (ledipasvir/sofosbuvir), have also been shown to achieve cure rates of over 90% in clinical trials.

It’s important to note that the exact cure rate may vary depending on the patient population, including factors such as genotype, prior treatment history, and underlying health conditions.

However, these new treatments have greatly improved the prognosis for patients with HCV, and have been a significant advancement in the management of this virus.

Dr. Michael Dodd

As a nurse, I would like to add that these high cure rates are a testament to the effectiveness of DAAs, and have led to a reduction in the burden of liver disease in many populations.

However, it’s also important to emphasize that HCV treatment must be individualized, and that patients should discuss the best treatment options for their specific situation with their healthcare provider.

Additionally, patients who are cured of HCV infection should still be monitored for potential long-term liver complications and should continue to take precautions to prevent transmission of the virus.

Kris Miller R.N.